AAV Serotype Comparison for LRRK2 Knockdown in PD

🧫 Experiment Protocol ValidationParkinson's DiseaseAAVmouseproposed

# AAV Serotype Comparison for LRRK2 Knockdown in PD ## Background and Rationale Leucine-rich repeat kinase 2 (LRRK2) mutations are the most common genetic cause of Parkinson's disease (PD), with G2019S being the most prevalent pathogenic variant. LRRK2 gain-of-function mutations lead to increased kinase activity, resulting in neuronal dysfunction and degeneration. Adeno-associated virus (AAV)-mediated gene therapy represents a promising therapeutic approach, but optimal serotype selection is critical for achieving effective transduction and therapeutic efficacy in dopaminergic neurons. This validation study aims to systematically compare multiple AAV serotypes for LRRK2 knockdown efficiency in a mouse model of PD. The experimental design involves stereotactic injection of different AAV serotypes (AAV1, AAV2, AAV5, AAV9, and AAVrh10) carrying shRNA targeting LRRK2 into the substantia nigra of C57BL/6 mice. We will evaluate transduction efficiency, LRRK2 knockdown levels, dopaminergic neuron survival, and behavioral improvements across serotypes. Key measurements include immunohistochemical analysis of tyrosine hydroxylase-positive neurons, LRRK2 protein levels by Western blot, striatal dopamine content by HPLC, and motor function assessment using rotarod and cylinder tests. This comparative analysis addresses a critical knowledge gap in AAV-mediated PD gene therapy, as serotype selection significantly impacts therapeutic outcomes. The innovation lies in the head-to-head comparison of multiple clinically relevant AAV serotypes using standardized conditions and comprehensive outcome measures. Results will inform optimal vector selection for future preclinical studies and clinical translation, potentially accelerating the development of LRRK2-targeted gene therapies for PD patients. This experiment directly tests predictions arising from the following hypotheses: - **Blood-Brain Barrier SPM Shuttle System** - **Synthetic Biology BBB Endothelial Cell Reprogramming** - **Magnetosonic-Triggered Transferrin Receptor Clustering** - **Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modulation** - **Piezoelectric Nanochannel BBB Disruption** ## Experimental Protocol Phase 1 (Week 0): Prepare AAV vectors encoding LRRK2 shRNA in serotypes AAV1, AAV2, AAV5, AAV9, and AAVrh10 (1×10^12 vg/ml). Acclimate 60 male C57BL/6 mice (8-10 weeks) for one week. Phase 2 (Week 1): Perform stereotactic surgery under isoflurane anesthesia. Inject 2μl of AAV vectors bilaterally into substantia nigra (coordinates: AP -3.1mm, ML ±1.2mm, DV -4.2mm) using Hamilton syringe (n=10 per serotype). Include control group with saline injection. Phase 3 (Weeks 2-8): Monitor animals weekly for weight and general health. Perform behavioral assessments at weeks 4, 6, and 8 including rotarod performance (5 trials, 4-40 rpm acceleration) and cylinder test for forepaw asymmetry. Phase 4 (Week 8): Sacrifice animals via transcardial perfusion with 4% paraformaldehyde. Collect brain tissue for immunohistochemistry and separate cohort for biochemical analysis. Phase 5 (Weeks 9-12): Process tissue sections for tyrosine hydroxylase and LRRK2 immunostaining. Perform stereological counting of dopaminergic neurons in substantia nigra. Analyze LRRK2 protein levels by Western blot and measure striatal dopamine content by HPLC. Quantify AAV transduction efficiency using GFP reporter expression and vector genome copy number by qPCR. ## Expected Outcomes - AAV9 and AAVrh10 will demonstrate superior transduction efficiency (>70% of dopaminergic neurons) compared to AAV1, AAV2, and AAV5 (<50% transduction) - LRRK2 protein levels will be reduced by 60-80% in substantia nigra with AAV9 and AAVrh10, compared to 30-50% reduction with other serotypes - AAV9 and AAVrh10 groups will show significantly improved rotarod performance (>150% of baseline) and reduced forepaw asymmetry (<20%) compared to controls - Dopaminergic neuron survival will be highest with AAV9 and AAVrh10 (>90% of normal), with AAV2 showing intermediate protection (70-80%) - Striatal dopamine levels will correlate with transduction efficiency, with AAV9 and AAVrh10 maintaining >80% of normal dopamine content - Vector genome copy numbers will be 2-3 fold higher in substantia nigra with AAV9 and AAVrh10 compared to other serotypes ## Success Criteria - • Achieve >70% transduction efficiency of dopaminergic neurons with at least one AAV serotype - • Demonstrate >60% LRRK2 knockdown with statistical significance (p<0.05) in best-performing serotype - • Show significant improvement in rotarod performance (>130% of control) with top serotype - • Maintain >85% dopaminergic neuron survival compared to untreated controls - • Achieve striatal dopamine levels >75% of normal with optimal serotype - • Establish clear hierarchy of serotype performance with statistical separation between top and bottom performers

Source: wiki

🧫 Experiment Extras

🟢 Parkinson's Disease 🧠 Neurodegeneration

📊 Evidence Profile

0 supporting 0 contradicting 0 neutral

🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found